TSLA
Tesla
-- 355.840 NVDA
NVIDIA
-- 138.850 INTC
Intel
-- 23.600 NBIS
NEBIUS
-- 44.490 PLTR
Palantir
-- 119.160 
NEWS
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
Agenus (NASDAQ: AGEN) will present new data on two promising immunotherapy candidates at the SITC 2024 Annual Meeting in Houston. The presentations will feature botensilimab, an Fc-enhanced anti-CTLA-4 antibody showing efficacy in treatment-resistant cancers, and AGEN1721, a first-in-class bifunctional antibody targeting FAP and TGFβ.
Botensilimab enhances both innate and adaptive immunity, demonstrating effectiveness in glioblastoma, melanoma, colorectal, pancreatic, and breast cancers. AGEN1721 works by remodeling the tumor microenvironment, depleting cancer-associated fibroblasts, and neutralizing TGFβ's immunosuppressive effects, transforming cold tumors into immune-responsive environments.
Botensilimab enhances both innate and adaptive immunity, demonstrating effectiveness in glioblastoma, melanoma, colorectal, pancreatic, and breast cancers. AGEN1721 works by remodeling the tumor microenvironment, depleting cancer-associated fibroblasts, and neutralizing TGFβ's immunosuppressive effects, transforming cold tumors into immune-responsive environments.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
8158
Followers
50
Following
93K
Visitors
Follow
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Krystian 1983 : Discount just remmember last year when this run to 20 dollars share. Is happen soon
